I initiated coverage on Paratek Pharmaceuticals (PRTK). PRTK offers significant upside from current levels. Even based on conservative estimates, I got a fair value of $28 for the stock, which represents upside of more than 100% from current levels. The full report on PRTK can be read here. Following the recent secondary offering, there is no dilution risk in PRTK in the medium term. The company also has the option of obtaining non-dilutive funding in the future.